The FDA has approved Trilipix (fenofibric acid), a delayed-release capsule for use along with diet to treat dyslipidemia. Trilipix is the first fibrate to be approved for use in combination with a statin. In certain patients, treatment guidelines recommend the combination of a fibrate with a statin to further improve lipid levels. Trilipix has not been shown to prevent heart disease or heart attack.
Trilipix was studied in 2,698 patients with mixed dyslipidemia. These studies demonstrated that Trilipix used in combination with the most commonly prescribed statins helped patients manage all three key lipids better than the corresponding therapies alone.
Treatment guidelines endorsed by the National Cholesterol Education Program, the American College of Cardiology, and the American Heart Association have called for more aggressive management of lipids, including a lower LDL goal for many patients, as well as more aggressive management of HDL and triglycerides.
Full Prescribing Information is available here.